Annovis Bio, Inc. develops buntanetap, an investigational oral therapy for neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease. News about ANVS commonly centers on clinical development of buntanetap, peer-reviewed publications, biomarker data, safety findings, and scientific presentations related to the company’s multi-protein approach to neurodegeneration.
Recurring updates also cover intellectual-property protection for buntanetap and related compounds, collaborations that add digital biomarker technology to Parkinson’s disease research, corporate financing, annual financial results, and other public-company developments tied to funding, governance, and clinical-regulatory disclosure.
Annovis Bio, Inc. CEO Maria Maccecchini issued a letter to stockholders discussing Phase II/III data from the Alzheimer's study. The company remains committed to developing a drug for Alzheimer's and Parkinson's diseases, despite recent setbacks. The Phase II/III study provided valuable insights for an improved Phase III trial, focusing on early and mild Alzheimer's patients.
Annovis Bio announced statistically significant Phase II/III data in patients with early Alzheimer’s disease for buntanetap, an oral molecule that reduces production of toxic proteins. The study showed a significant improvement in ADAS-Cog 11 scores in mild AD patients, with a 3.3-point improvement over placebo. Plasma Tau protein levels were reduced, supporting the efficacy. Annovis plans to conduct a Phase III trial in biomarker-positive early AD patients.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.